732P Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as a first-line treatment for endometrial cancer (EC): Progression-free survival (PFS) by clinical factors in DUO-E

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 35; p. S557
Main Authors Blank, S.V., McCollum, M., Anderson, C., Pennington, K., Salinas, E., Richardson, D.L., Slomovitz, B.M., Kim, B-G., Liu, J., Mori, M., Guette, P.L. Ramos, Joseph de Pádua, C., Martinez-Garcia, J., Papadimitriou, C., Grisan, K., Póka, R.L., Kowgier, M., Del Rosario, P.M.D., Van Nieuwenhuysen, E., Westin, S.
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.09.2024
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
DOI:10.1016/j.annonc.2024.08.794